IMPACT OF PRIOR TREATMENT ON PFS FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS RANDOMIZED TO LENALIDOMIDE VS INVESTIGATOR'S CHOICE: A SUBGROUP ANALYSIS OF THE PHASE II MCL-002 (SPRINT) STUDY

M. Trneny; T. Lamy; J. Walewski; D. Belada; J. Mayer; J. Radford; W. Jurczak; F. Morschhauser; J. Alexeeva; S. Rule; T. Biyukov; M. Patturajan; M. L. Casadebaig Bravo; L. Arcaini

IMPACT OF PRIOR TREATMENT ON PFS FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS RANDOMIZED TO LENALIDOMIDE VS INVESTIGATOR'S CHOICE: A SUBGROUP ANALYSIS OF THE PHASE II MCL-002 (SPRINT) STUDY

M. Trneny, T. Lamy, J. Walewski, D. Belada, J. Mayer, J. Radford, W. Jurczak, F. Morschhauser, J. Alexeeva, S. Rule, T. Biyukov, M. Patturajan, M. L. Casadebaig Bravo, L. Arcaini

Research output: Contribution to journal › Article › peer-review

Original language	Undefined
Journal	Haematologica
Volume	100
Issue number	4
Publication status	Published - 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Trneny, M., Lamy, T., Walewski, J., Belada, D., Mayer, J., Radford, J., Jurczak, W., Morschhauser, F., Alexeeva, J., Rule, S., Biyukov, T., Patturajan, M., Bravo, M. L. C., & Arcaini, L. (2015). IMPACT OF PRIOR TREATMENT ON PFS FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS RANDOMIZED TO LENALIDOMIDE VS INVESTIGATOR'S CHOICE: A SUBGROUP ANALYSIS OF THE PHASE II MCL-002 (SPRINT) STUDY. Haematologica, 100(4).

@article{fc781d53d7f04c47b28a4c180587a873,

title = "IMPACT OF PRIOR TREATMENT ON PFS FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS RANDOMIZED TO LENALIDOMIDE VS INVESTIGATOR'S CHOICE: A SUBGROUP ANALYSIS OF THE PHASE II MCL-002 (SPRINT) STUDY",

author = "M. Trneny and T. Lamy and J. Walewski and D. Belada and J. Mayer and J. Radford and W. Jurczak and F. Morschhauser and J. Alexeeva and S. Rule and T. Biyukov and M. Patturajan and Bravo, {M. L. Casadebaig} and L. Arcaini",

year = "2015",

language = "Undefined",

volume = "100",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "4",

}

Trneny, M, Lamy, T, Walewski, J, Belada, D, Mayer, J, Radford, J, Jurczak, W, Morschhauser, F, Alexeeva, J, Rule, S, Biyukov, T, Patturajan, M, Bravo, MLC & Arcaini, L 2015, 'IMPACT OF PRIOR TREATMENT ON PFS FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS RANDOMIZED TO LENALIDOMIDE VS INVESTIGATOR'S CHOICE: A SUBGROUP ANALYSIS OF THE PHASE II MCL-002 (SPRINT) STUDY', Haematologica, vol. 100, no. 4.

TY - JOUR

T1 - IMPACT OF PRIOR TREATMENT ON PFS FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS RANDOMIZED TO LENALIDOMIDE VS INVESTIGATOR'S CHOICE

T2 - A SUBGROUP ANALYSIS OF THE PHASE II MCL-002 (SPRINT) STUDY

AU - Trneny, M.

AU - Lamy, T.

AU - Walewski, J.

AU - Belada, D.

AU - Mayer, J.

AU - Radford, J.

AU - Jurczak, W.

AU - Morschhauser, F.

AU - Alexeeva, J.

AU - Rule, S.

AU - Biyukov, T.

AU - Patturajan, M.

AU - Bravo, M. L. Casadebaig

AU - Arcaini, L.

PY - 2015

Y1 - 2015

UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000361204901007&KeyUID=WOS:000361204901007

M3 - Article

SN - 0390-6078

VL - 100

JO - Haematologica

JF - Haematologica

IS - 4

ER -

IMPACT OF PRIOR TREATMENT ON PFS FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS RANDOMIZED TO LENALIDOMIDE VS INVESTIGATOR'S CHOICE: A SUBGROUP ANALYSIS OF THE PHASE II MCL-002 (SPRINT) STUDY

UN SDGs

Other files and links

Cite this